SCHEMBL5337292

SCHEMBL5337292

Cc1nc(N)c2nc(C(C)C3CC3)n(CCOCCNC(=O)Nc3cccnc3)c2c1C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 3/20 0.38
NFE2L2 Q16236 3/20 0.38
CDK2 P24941 2/20 0.38
FLT4 P35916 1/20 0.38
CYP1A2 P05177 1/20 0.35
ERN1 O75460 2/20 0.35
NAMPT P43490 1/20 0.35
EPHX2 P34913 2/20 0.34
FPR2 P25090 1/20 0.34
ALDH1A1 P00352 1/20 0.33
CYP3A4 P08684 1/20 0.33
CACNA1G O43497 2/20 0.33
CACNA1H O95180 2/20 0.33
CACNA1I Q9P0X4 2/20 0.33
MEN1 O00255 1/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
KMT2A Q03164 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
CCNE2 O96020 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5340187 0.89 CDK2 (0.39) KEAP1NFE2L2CDK2FLT4CYP1A2
SCHEMBL5336995 0.88 TLR8 (0.43) CYP1A2ALDH1A1CYP3A4MEN1KMT2A
SCHEMBL5869938 0.87 KEAP1 (0.38) KEAP1NFE2L2CDK2FLT4CYP1A2
SCHEMBL5333512 0.85 KEAP1 (0.41) KEAP1NFE2L2CDK2FLT4CYP1A2
SCHEMBL5337301 0.84 KEAP1 (0.40) KEAP1NFE2L2CDK2FLT4CYP1A2
SCHEMBL5342022 0.83
SCHEMBL5340468 0.82 CDK2 (0.42) KEAP1NFE2L2CDK2FLT4CYP1A2
SCHEMBL5340168 0.82 CDK2 (0.42) KEAP1NFE2L2CDK2FLT4CYP1A2
SCHEMBL4795296 0.82 CYP1A2 (0.31) CYP1A2MEN1KMT2A
SCHEMBL5335418 0.81 EPHX2 (0.35) EPHX2ALDH1A1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7220758-B2 Ether substituted imidazopyridines 3M INNOVATIVE PROPERTIES COMPANY (US) 2007-05-22 US disclosed
US-20060252792-A1 ETHER SUBSTITUTED IMIDAZOPYRIDINES 3M INNOVATIVE PROPERTIES COMPANY 2006-11-09 US disclosed
US-7125890-B2 Ether substituted imidazopyridines 3M INNOVATIVE PROPERTIES COMPANY (US) 2006-10-24 US disclosed
US-20050032830-A1 Immunology for viral diseases and biosynthesis of cytokines of anticancer drugs for tumors 3M INNOVATIVE PROPERTIES COMPANY 2005-02-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060252792-A1 ETHER SUBSTITUTED IMIDAZOPYRIDINES IL2, IL4, MYD88 KEAP1 820/4885NFE2L2 607/4885CDK2 1026/4885
US-20050032830-A1 Immunology for viral diseases and biosynthesis of cytokines of anticancer drugs for tumors IL2, IFNG, TSLP KEAP1 482/4885NFE2L2 1020/4885CDK2 2068/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.